| Name | Title | Contact Details |
|---|
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
First Health Group Corporation is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Longevity secrets from the worlds longest-lived people.
Insight Imaging is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
QuVa Pharma, Inc. is a newly-formed national platform for sterile compounding pharmacy services led by two experienced industry executives that has received a majority equity commitment from Bain Capital Private Equity to support the company’s creation and expansion plans. As part of its formation, QuVa Pharma has acquired the assets of the compounding services division of a company leader in the field of parenteral and management services, including its state-of-the-art 503B manufacturing facility in Sugar Land, Texas.